Spruce Biosciences, Inc. SPRB shares fell in Tuesday premarket trading after the company priced a public offering of common ...

Spruce Biosciences (SPRB) has priced its public offering of 1.15M common stock shares at $50.00 each.  It is also offering pre-funded warrants to a specific investor for 50K shares at $49.99 each. The ...

Spruce Biosciences, Inc. (SPRB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates - ...

“In the interim, the CAHmelia-204 and CAHptain-205 clinical trials will be discontinued, and we will be winding down Spruce’s investment in tildacerfont for the treatment of CAH as we conserve ...

Spruce Biosciences, Inc. ("Spruce Biosciences") (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with ...

Spruce Biosciences, Inc. (SPRB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SPRB's 50-day simple moving average broke out above ...

The average one-year price target for Spruce Biosciences (NasdaqCM:SPRB) has been revised to $235.11 / share. This is an increase of 10.02% from the prior estimate of $213.69 dated December 18, 2025.

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...